Browse By

Category Archives: Biotech&Pharma

[Biotech&Pharma] Why This Biotech's Next Chapter Is 'TBD' Amid Deal-Making Dearth

Gilead Sciences' (GILD) next chapter is still murky, an analyst said Friday, noting a dearth of expected takeovers among biotech stocks during the J.P. Morgan Healthcare Conference. X {“@context”:””,”@type”:”VideoObject”,”name”:”How To Buy Stocks: Buying Checklist”,”description”:”How do you know if you're buying stocks at the right time?

[Biotech&Pharma] Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum

BURLINGAME, Calif., Feb. 01, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1/1b clinical trial of CPI-818, the Company's

[Biotech&Pharma] Why This Top-Notch Biotech Stock Just Plunged By Double Digits

Shares of Arrowhead Pharmaceuticals (ARWR) crashed to a two-month low Tuesday after an analyst initiated coverage of ARWR stock with an underperform rating. X {“@context”:””,”@type”:”VideoObject”,”name”:”Investing Strategies: Trading Tactics And Portfolio Strategies For 2020″,”description”:”With 2019 quickly coming to a close, we're dissecting trading tactics to consider

[Biotech&Pharma] Rapid Dose Therapeutics Receives Funding for Scale-Up Manufacturing and Commercialization of Quickstrip™ Product

BURLINGTON, Ontario, Feb. 04, 2020 (GLOBE NEWSWIRE) — Rapid Dose Therapeutics Corp. (CSE:DOSE) (“RDT” or the “Corporation“) (“RDT” or the “Corporation“) is pleased to announce the company has secured government funding of $400,000 from The National Research Council of Canada Industrial Research Assistance (NRC-IRAP), to support